Prostate Cancer Reports


Volume 2 Supplement 4
 April 2014
Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Supplement 4, April 2014

CONTENTS



Diagnosis and evaluation
Nomograms
Overall management
Recurrence
Staging
Treatment




Sanders M, Nandalur K, Tyagi N, Schulze D, Yan D, Krauss D.
Quantifying tumor aggressiveness using diffusion-weighted MRI for prostate cancer.
Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S10. doi: 10.1016/j.prro.2013.01.035. Epub 2013 Mar 25.
Abstract | Full text | Related citations



Kattan MW, Wheeler TM, Scardino PT.
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.
J Clin Oncol. 1999 May;17(5):1499-507.
Abstract | Full text | Related citations



Guidelines

NCCN Guidelines
Prostate Cancer

NCCN Clinical Practice Guidelines in Oncology 2012
Abstract | Full text




D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer.
J Clin Oncol. 2000 Mar 13;18(6):1164-72.
Abstract | Full text | Related citations


Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr.
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Cancer. 2003 Dec 1;98(11):2344-50. Epub 2003 Oct 20.
Abstract | Full text | Related citations


Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr; SEARCH Database Study Group.
Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
J Urol. 2003 Jun;169(6):2136-41.
Abstract | Related citations


Lohm G, Bottke D, Jamil B, Miller K, Neumann K, Bartkowiak D, Hinkelbein W, Wiegel T.
Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.
World J Urol. 2013 Apr;31(2):423-8. doi: 10.1007/s00345-012-0860-y. Epub 2012 Mar 30.
Abstract | Related citations


Sejima T, Iwamoto H, Masago T, Morizane S, Yao A, Isoyama T, Kadowaki H, Takenaka A.
Low pre-operative levels of serum albumin predict lymph node metastases and ultimately correlate with a biochemical recurrence of prostate cancer in radical prostatectomy patients.
Cent European J Urol. 2013;66(2):126-32. doi: 10.5173/ceju.2013.02.art3. Epub 2013 Aug 13.
Abstract | Full text | Related citations


Symon Z.
Prostate Cancer: Biochemical Failure, Risk Stratification, and Metastatic Disease.
Medscape Oncology, 2003 Jun 6.
Abstract | Full text


Wajsman Z.
Prostate cancer recurrence - new prognostic factors are needed.
Cent European J Urol. 2013;66(2):133-4. doi: 10.5173/ceju.2013.02.art4.
Abstract | Full text | Related citations


Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI.
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Eur Urol. 2009 Feb;55(2):412-19. doi: 10.1016/j.eururo.2008.11.005. Epub 2008 Nov 21.
Abstract | Full text | Related citations


Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W.
Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16. doi: 10.1016/j.ijrobp.2008.06.1922. Epub 2008 Oct 27.
Abstract | Related citations


Yoon JH, Chen MH, Renshaw AA, Richie JP, D'Amico AV.
Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer.
Urology. 2002 Sep;60(3):454-7.
Abstract | Related citations


Risk stratification

Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H; Genitourinary Radiation Oncologists of Canada.
Pre-treatment risk stratification of prostate cancer patients: A critical review.
Can Urol Assoc J. 2012 Apr;6(2):121-7. doi: 10.5489/cuaj.11085.
Abstract | Full text | Related citations


Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
Eur Urol. 2013 Dec;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033. Epub 2013 Mar 23.
Abstract | Full text | Related citations



Gleason score

Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI.
Contemporary grading for prostate cancer: implications for patient care.
Eur Urol. 2013 May;63(5):892-901. doi: 10.1016/j.eururo.2012.10.015. Epub 2012 Oct 17
Abstract | Full text | Related citations



Guimaraes MS, Quintal MM, Meirelles LR, Magna LA, Ferreira U, Billis A.
Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy.
Int Braz J Urol. 2008 Jan-Feb;34(1):23-9.
Abstract | Full text | Related citations



Helpap B, Egevad L.
Modified Gleason grading. An updated review.
Histol Histopathol. 2009 May;24(5):661-6
Abstract | Full text | Related citations



First-line treatment

Grossgold E, Given R, Ruckle H, Jones JS.
Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome?
Urology. 2014 Feb;83(2):379-83. doi: 10.1016/j.urology.2013.08.061. Epub 2013 Dec 7.
Abstract | Related citations